Ranjana Mariyam Raju
09/10/2026, 10:26 AMBilal Asser
09/10/2026, 11:38 AMRanjana Mariyam Raju
09/10/2026, 11:52 AMBilal Asser
09/10/2026, 12:36 PMBilal Asser
09/10/2026, 12:37 PMRanjana Mariyam Raju
09/10/2026, 3:15 PMBilal Asser
09/11/2026, 8:02 AMBilal Asser
09/14/2026, 6:39 AMBilal Asser
09/15/2026, 10:27 AMsubworkflows/gatk_Niare.nf (working filename).
I have only organised and included the modules that exist on nf-core so far. Moving onto working out the I/O and whether the steps that do not exist as modules can be omitted
I'll think about how the task can be broken up between two people once I get to know it better 🙂Ranjana Mariyam Raju
09/15/2026, 11:16 AMBilal Asser
09/15/2026, 11:24 AMBA_contrib
My thinking is that I try to deviate as little as possible from what is on github since that was validated and will make our tool validation easier later. I am on cleansam because there was no need to include SamFormatConverter for example. There is no module for DepthOfCoverage but we can cross that bridge when we get to it
Thanks for flagging those issues especially the one about training data. My experience with gatk is from using it on RNASeq data, where VariantRecalibrator is not part of the workflow https://gatk.broadinstitute.org/hc/en-us/articles/360035531192-RNAseq-short-variant-discovery-SNPs-Indels
As for the ploidy issue...Bilal Asser
09/15/2026, 11:28 AMfor loop body (this is pipeline_full.sh from the github repo) you can see the arg -ploidy 6 . I assume this is the "Pipeline 2" from the paper. Not quite sure what you meant by "not the core pipeline", can you clarify if still relevant?Bilal Asser
09/15/2026, 11:29 AMRanjana Mariyam Raju
09/15/2026, 11:39 AMBilal Asser
09/15/2026, 11:48 AMpathogensurveillance which is why a new pipeline was warranted. For the few, but very important (in public health), pathogens where treatment efficacy benefits from MOI analysis.
The first specific example this pipeline should tackle is malaria samples from mosquitoes. There, the MOI information is intended to see what resistances to antimalarial drugs are present in a particular space and time. That way, antimalarial drug distribution can be more data-driven/have stronger evidence base/maybe timeline if we can get a database going for outputs.
(sorry for any errors or lack of clarity, there is some construction noise. Let me know if I should rephrase anything)Bilal Asser
09/15/2026, 11:49 AM-ploidy 6 is what we should go with based on the Niare et al evidenceBilal Asser
09/15/2026, 11:51 AMVariantRecalibratorRanjana Mariyam Raju
09/15/2026, 11:53 AMBilal Asser
09/15/2026, 11:54 AMBilal Asser
09/15/2026, 11:56 AMRanjana Mariyam Raju
09/15/2026, 11:58 AMBilal Asser
09/15/2026, 12:03 PMBilal Asser
09/15/2026, 12:10 PMBA_contrib and I'm taking a breakRanjana Mariyam Raju
09/15/2026, 12:10 PMBilal Asser
09/15/2026, 12:13 PMBilal Asser
09/17/2026, 4:17 PMRanjana Mariyam Raju
09/17/2026, 4:28 PMBilal Asser
09/17/2026, 4:37 PMRanjana Mariyam Raju
09/17/2026, 4:41 PM